Rocket Lab (RKLB) shares traded near $50–53 during the week of October 19, 2026, pressured by the mid-month announcement delaying Neutron’s debut to 2027 amid carbon-fiber manufacturing defects. This setback overshadowed a string of Electron successes, including the 98th mission on October 23 that deployed three HawkEye 360 satellites, and progress on the pending Iridium acquisition expected to close by mid-2027 and roughly double revenue. Analysts maintained a moderate buy consensus with average 12-month targets near $102, citing robust launch backlog and Q3 revenue growth to roughly $256 million, though the company continues posting losses ahead of the November 9 earnings release. The stock’s elevated beta and distance below key moving averages reflect sensitivity to development timelines and sector sentiment.